Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers

33Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed. Cases were compared with a single-institution control cohort. RESULTS: Of 36 cases, 86.1% concerned BRCA1 mutation carriers. The median age of the patients was 52 years (range, 30-71 years) at the time of risk-reducing surgery and 60 years (range, 37-75 years) at the time of diagnosis of peritoneal carcinomatosis. The median interval between the 2 events was 54.5 months (range, 11-292 months). Peritoneal carcinomatosis was mostly high-grade serous carcinoma. Histopathological details of the RRSO specimens were retrieved in 8 cases; 5 (62.5%) were found to have serous tubal intraepithelial carcinoma and 1 had epithelial atypia. Cases were older (P =.025) at the time of risk-reducing surgery and harbored more serous tubal intraepithelial carcinomas (P

Cite

CITATION STYLE

APA

Harmsen, M. G., Piek, J. M. J., Bulten, J., Casey, M. J., Rebbeck, T. R., Mourits, M. J., … de Hullu, J. A. (2018). Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer, 124(5), 952–959. https://doi.org/10.1002/cncr.31211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free